159 related articles for article (PubMed ID: 15249764)
1. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy.
Bittner V
Prev Cardiol; 2004; 7(3):122-6; quiz 129-30. PubMed ID: 15249764
[TBL] [Abstract][Full Text] [Related]
2. Non-high-density lipoprotein cholesterol and cardiovascular disease.
Bittner V
Curr Opin Lipidol; 2003 Aug; 14(4):367-71. PubMed ID: 12865734
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
[TBL] [Abstract][Full Text] [Related]
7. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
8. [How to manage lipid profiles and their interpretation in patients with coronary heart disease?].
Farnier M
Presse Med; 2009 Jun; 38(6):958-63. PubMed ID: 19376680
[TBL] [Abstract][Full Text] [Related]
9. Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment.
Ferguson EE
Dis Mon; 2000 Jul; 46(7):421-503. PubMed ID: 10943222
[TBL] [Abstract][Full Text] [Related]
10. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Boden WE
Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
[TBL] [Abstract][Full Text] [Related]
12. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).
Wong ND; Chuang J; Wong K; Pham A; Neff D; Marrett E
Am J Cardiol; 2013 Aug; 112(3):373-9. PubMed ID: 23642513
[TBL] [Abstract][Full Text] [Related]
13. Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials.
Xydakis AM; Ballantyne CM
Curr Opin Cardiol; 2003 Nov; 18(6):503-9. PubMed ID: 14597892
[TBL] [Abstract][Full Text] [Related]
14. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.
Desmeules S; Arcand-Bossé JF; Bergeron J; Douville P; Agharazii M
Am J Kidney Dis; 2005 Jun; 45(6):1067-72. PubMed ID: 15957136
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2011 Jul; 108(1):40-6. PubMed ID: 21565322
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein lipids and the prevalence of hyperlipidaemia in rural India.
Gupta R; Gupta HP; Kumar N; Joshi AK; Gupta VP
J Cardiovasc Risk; 1994 Aug; 1(2):179-84. PubMed ID: 7606632
[TBL] [Abstract][Full Text] [Related]
17. Non-HDL cholesterol as a measure of atherosclerotic risk.
Packard CJ; Saito Y
J Atheroscler Thromb; 2004; 11(1):6-14. PubMed ID: 15067193
[TBL] [Abstract][Full Text] [Related]
18. Triglyceride as a risk factor for coronary artery disease.
Gotto AM
Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
[TBL] [Abstract][Full Text] [Related]
19. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
20. Trends in lipids and lipoproteins in US adults, 1988-2010.
Carroll MD; Kit BK; Lacher DA; Shero ST; Mussolino ME
JAMA; 2012 Oct; 308(15):1545-54. PubMed ID: 23073951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
